Microbiology and Infection · uk
How does Candida auris survive drug attacks? Genome duplication and CRZ1 mutations reveal clues to survival
Leaving culture plates for a few extra days revealed a previously undetected population of surviving fungi. A new study offers clues to the gap between drug susceptibility test results and treatment outcomes, while reminding researchers to pay attention to the adaptability of minority populations.
When tests indicate that a drug should work but an infection remains difficult to control, the problem may lie in a minority fungal population that has yet to be detected. A UK research team found that Candida auris can continue growing under antifungal drug pressure by increasing the number of copies of its entire genome and through mutations in CRZ1, a gene involved in cell wall regulation, providing a new biological explanation for treatment failure.
A team from the University of Exeter and City St George’s, University of London was conducting drug resistance tests when culture plates were accidentally left for longer than the prescribed period. Several days later, the researchers found that a small group of cells had grown even after exposure to very high drug concentrations. The extended wait revealed survival that had not become apparent within the original assessment period.
Subsequent analysis showed that the surviving cells had increased the number of copies of their entire genome. The population also showed different growth rates: some cells grew slowly, while others grew faster. This difference suggests that fungal populations under drug pressure are not uniform, and that a minority of cells may adapt to stress through different pathways.
The faster-growing cells carried various CRZ1 mutations. This gene helps regulate cell wall synthesis; further testing by the research team found that cells carrying the relevant mutations maintained rapid growth, while their cell walls also appeared to remain intact during drug exposure. The study thus extended the search for clues to survival mechanisms beyond common mutations in drug targets to genome copy number and cell wall regulation.
The finding is relevant to poor responses to treatment with echinocandin antifungal drugs. According to the university’s October 15 announcement, the study had been published in Nature Communications; a university-provided article published by Phys.org on the same day also described these results, but still listed the paper as forthcoming at that time. Both reports came from the same research team and cannot be regarded as independent replication.
The practical significance of the study is that it suggests the observation period and interpretation methods used in drug susceptibility testing may affect whether minority populations of surviving fungi can be identified. However, publicly available reports have not yet established how common this mechanism is in patient infections, nor have they demonstrated that extending culture time can improve treatment decisions. These findings therefore do not establish that all discrepancies between test results and treatment outcomes are caused by the same mechanism.
Through Fungi-CARE, a project led by the University of Exeter and funded by UK Research and Innovation, the team is exploring strategies including combinations of antifungal drugs. Further validation is still needed to move from identifying survival pathways to establishing reliable tests and effective treatments. For now, this accident in the culture plates has allowed researchers to see an adaptive process that could easily have been overlooked.